Ep. 231 - Biosecure Revised. Plus: Venture Rounds, Deals of Note

Lawmakers’ changes to the Biosecure Act create breathing room for U.S. biopharma companies to move on from Chinese CDMOs, Washington Editor Steve Usdin said. On the latest BioCentury This Week podcast, Usdin and his BioCentury colleagues discuss what the revisions mean for biotechs and what’s next for the legislation, plus how WuXi AppTec is defending itself against the bill’s allegations. Director of Biopharma Intelligence Paul Bonanos discusses last week’s surge in venture activity, including the largest biotech round, a $200 million series C by Lonnie Moulder’s Zenas BioPharma, as well as recent deals of note, including one for Maze Therapeutics. The biotech found a new partner for its Pompe disease program in Shionogi, months after Sanofi pulled out of a deal for the therapy amid FTC scrutiny. This week’s podcast is sponsored by Nxera Pharma. View full story: https://www.biocentury.com/article/65240200:01 - Sponsor Message: Nxera Pharma03:24 - Biosecure Revisions09:34 - WuXi AppTec Responds14:42 - Venture Raises19:32 - Deals of NoteReach us by sending a text